 3. Consequently, the diagnostic delay has lead to lack of data on optimal treatment in early PA. In the current guideline NHG-guideline Cardiovascular risk management a regimen of antihypertensive drugs is advised, and only if hypertension is refractory for 6 months patients are referred. It is unknown if hypertension is resistant to therapy in the initial phase of PA. If not, this would also argue for early biochemical screening for PA, because even if blood pressure is controlled, the detrimental effect of aldosterone itself will go on unopposed. It is therefore required to study the response to antihypertensive drugs not MRA in these patients. 